Skip to main content
SpringerLink
Log in

Neuroendocrine Neoplasms of the Gastrointestinal Tract

  • Chapter
  • First Online:
Practical Gastrointestinal Pathology

Part of the book series: Practical Anatomic Pathology ((PAP))

  • 1515 Accesses

Abstract

Considerable confusion surrounds neuroendocrine neoplasms, as terminology and understanding of their biological behavior continues to evolve. In this chapter, a series of questions and answers is presented addressing what features define neuroendocrine neoplasms; definitions of neuroendocrine tumors, neuroendocrine carcinomas, and other rarer neuroendocrine neoplasms; and how to diagnose, grade, and stage neuroendocrine neoplasms. Particular attention is paid to current concepts and updates regarding high-grade neuroendocrine tumors, mixed adenoneuroendocrine carcinomas and mixed neuroendocrine-nonneuroendocrine neoplasms, updated tumor staging criteria, and novel insights into the genomic landscape of neuroendocrine neoplasms. Finally, examination of five real-world cases walks the reader through the approach to neuroendocrine neoplasms and explores many of the concepts introduced earlier in the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kimura N, Pilichowska M, Okamoto H, Kimura I, Aunis D. Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. Mod Pathol. 2000;13(2):140–6.

    Article  PubMed  CAS  Google Scholar 

  3. Chejfec G, Falkmer S, Grimelius L, et al. Synaptophysin. A new marker for pancreatic neuroendocrine tumors. Am J Surg Pathol. 1987;11(4):241–7.

    Article  PubMed  CAS  Google Scholar 

  4. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1(7275):238–9.

    Article  PubMed  CAS  Google Scholar 

  5. Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32(5):719–31.

    Article  PubMed  Google Scholar 

  6. Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang Y, Wang W, Jin K, et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165–74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer staging manual. 8th ed. Chicago, IL: American College of Surgeons; 2017. p. 351–406.

    Google Scholar 

  9. Reid MD, Bagci P, Ohike N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015;28(5):686–94.

    Article  PubMed  Google Scholar 

  10. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472:341–9.

    Article  PubMed  CAS  Google Scholar 

  11. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853–60.

    Article  PubMed  Google Scholar 

  12. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20(5):285–314.

    Article  PubMed  CAS  Google Scholar 

  13. Li Z, Yuan J, Wei L, et al. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors. Int J Clin Exp Pathol. 2015;8(6):7072–82.

    PubMed  PubMed Central  CAS  Google Scholar 

  14. Mohanty S, Bhardwaj N, Lugo H, et al. Diagnostic utility of SATB2 in determining the site of origin of well-differentiated neuroendocrine tumors. Pancreas. 2018;47(3):348.

    Google Scholar 

  15. Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol. 2013;24(4):184–90.

    Article  PubMed  CAS  Google Scholar 

  16. Uccella S, La Rosa S, Volante M, Papotti M. Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol. 2018;29(2):150–68.

    Article  PubMed  Google Scholar 

  17. Klimstra DS, Capella C, Arnold R, et al. Neuroendocrine neoplasms of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise N, editors. WHO classification of tumours of the digestive tract. 4th ed. Lyon, France: IARC Press; 2010. p. 714–177.

    Google Scholar 

  18. La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol. 2016;27(4):284–311.

    Article  PubMed  CAS  Google Scholar 

  19. De Mestier L, Cros J, Neuzillet C, et al. Digestive system mixed neuroendocrine-nonneuroendocrine neoplasms. Neuroendocrinology. 2017;105(4):412–25.

    Article  PubMed  CAS  Google Scholar 

  20. Li Y, Yau A, Schaeffer D, et al. Colorectal glandular-neuroendocrine mixed tumor: pathologic spectrum and clinical implications. Am J Surg Pathol. 2011;35(3):413–25.

    PubMed  Google Scholar 

  21. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41(4):185–200.

    Article  PubMed  CAS  Google Scholar 

  22. Scherübel H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42(8):664–71.

    Article  Google Scholar 

  23. Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154–60.

    Article  PubMed  Google Scholar 

  24. Lupinacci RM, Dias AR, Mello ES, Kondo A. Minute type I gastric carcinoid with regional lymph node metastasis. Int J Surg Pathol. 2013;21(2):169–72.

    Article  PubMed  Google Scholar 

  25. Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19(46):8687–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.

    Article  PubMed  Google Scholar 

  27. Hung OY, Maithel SK, Willingham FF, Farris AB 3rd, Kauh JS. Hypergastrinemia, type 1 gastric carcinoid tumors: diagnosis and management. J Clin Oncol. 2011;29(25):e713–5.

    Article  PubMed  Google Scholar 

  28. Borch K, Ahrén B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differential treatments in relation to type. Ann Surg. 2005;242(1):64–73.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ooi A, Ota M, Katsuda S, Nakanishi I, Sugawara H, Takahashi I. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol. 1995;6(3):229–37.

    Article  PubMed  Google Scholar 

  30. Abraham SC, Carney JA, Ooi A, Choti MA, Argani P. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–75.

    Article  PubMed  Google Scholar 

  31. Nakata K, Aishima S, Ichimiya H, et al. Unusual multiple gastric carcinoids with hypergastrinemia: report of a case. Surg Today. 2010;40(3):267–71.

    Article  PubMed  Google Scholar 

  32. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008;15(1):229–41.

    Article  PubMed  Google Scholar 

  33. Tanaka S, Yamasaki S, Matsushita H, et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int. 2000;50(2):146–52.

    Article  PubMed  CAS  Google Scholar 

  34. Anlauf M, Perren A, Meyer CL, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128(5):1187–98.

    Article  PubMed  CAS  Google Scholar 

  35. Williams GT. Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology. 2007;50(1):30–41.

    Article  PubMed  CAS  Google Scholar 

  36. Donow C, Pipeleers-Marichal M, Schröder S, Stamm B, Heitz PU, Klöppel G. Surgical pathology of gastrinoma. Site, size, multicentricity, association of multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991;68(6):1329–34.

    Article  PubMed  CAS  Google Scholar 

  37. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinicopathological and epidemiological features. World J Gastroenterol. 2006;12(34):5440–6.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch. 2016;468(3):277–87.

    Article  PubMed  Google Scholar 

  39. Chen Y, Deshpande V, Ferrone C, et al. Primary lymph node gastrinoma: a single institution experience. Surgery. 2017;162(5):1088–94.

    Article  PubMed  Google Scholar 

  40. Anlauf M, Enosawa T, Henopp T, et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastasis in an MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol. 2008;32(7):1101–5.

    Article  PubMed  Google Scholar 

  41. Okubo Y, Yoshioka E, Suzuki M, et al. Diagnosis, pathological findings, and clinical management of gangliocytic paraganglioma: a systematic review. Front Oncol. 2018;8:291.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Li B, Li Y, Tian XY, Luo BN, Li Z. Malignant gangliocytic paraganglioma of the duodenum with distant metastases and a lethal course. World J Gastroenterol. 2014;20(41):15454–61.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79(6):1086–93.

    Article  PubMed  CAS  Google Scholar 

  44. Panzuto F, Campana D, Fazio N, et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology. 2012;96(1):32–40.

    Article  PubMed  CAS  Google Scholar 

  45. Choi AB, Maxwell JE, Keck KJ, et al. Is multifocality an indicator of aggressive behavior in small bowel neuroendocrine tumors? Pancreas. 2017;46(9):1115–20.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gangi A, Siegel E, Barmparas G, et al. Multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg. 2018;22(2):303–9.

    Article  PubMed  Google Scholar 

  47. Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C. Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Mod Pathol. 2014;27(9):1288–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Fata CR, Gonzalez RS, Liu E, Cates JM, Shi C. Mesenteric tumor deposits in midgut small intestinal neuroendocrine tumors are a stronger indication than lymph node metastasis for liver metastasis and poor prognosis. Am J Surg Pathol. 2017;41(1):128–33.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Woltering EA, Bergsland EK, Beyer DT, et al. Neuroendocrine tumors of the jejunum and ileum. In: Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer staging manual. 8th ed. Chicago, IL: American College of Surgeons; 2017. p. 375–87.

    Chapter  Google Scholar 

  50. Gonzalez RS, Cates JMM, Shi C. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. Mod Pathol. 2018;31(10):1560–6.

    Article  PubMed  Google Scholar 

  51. Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135–56.

    Article  PubMed  CAS  Google Scholar 

  52. Daskalakis K, Karakatsanis A, Stålberg P, Norlén O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017;104(1):69–75.

    Article  PubMed  CAS  Google Scholar 

  53. Iwafuchi M, Watanabe H, Ajoka Y, Shimoda T, Iwashita A, Ito S. Immunohistochemical and ultrastructural studies of twelve argentaffin and six argyrophil carcinoids of the appendix vermiformis. Hum Pathol. 1990;21(7):773–80.

    Article  PubMed  CAS  Google Scholar 

  54. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB. Goblet cell carcinoids and related tumors of the vermiform appendix. Am J Clin Pathol. 1990;94(1):27–35.

    Article  PubMed  CAS  Google Scholar 

  55. Warkel RL, Cooper PH, Helwig EB. Adenocarcinoid, a mucin-producing carcinoid tumor of the appendix: a study of 39 cases. Cancer. 1978;42(6):2781–93.

    Article  PubMed  CAS  Google Scholar 

  56. Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25(6):893–901.

    Article  PubMed  CAS  Google Scholar 

  57. Kim JY, Kim KS, Kim KJ, et al. Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis. Am J Surg Pathol. 2015;39(5):632–43.

    Article  PubMed  Google Scholar 

  58. Karpathakis A, Dibra H, Pipinikas C, et al. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22(1):250–8.

    Article  PubMed  CAS  Google Scholar 

  59. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–23.

    Article  PubMed  CAS  Google Scholar 

  60. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  PubMed  CAS  Google Scholar 

  61. Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8(8):e3004.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Sahnane N, Furlan D, Monti M, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015;22(1):35–45.

    Article  PubMed  CAS  Google Scholar 

  63. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36(4):601–11.

    Article  PubMed  Google Scholar 

  64. Vortmeyer AO, Lubensky IA, Merino MHJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89(19):1448–53.

    Article  PubMed  CAS  Google Scholar 

  65. Karkouche R, Bachet JB, Sandrini J, et al. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012;24(12):1430–7.

    Article  PubMed  Google Scholar 

  66. Scardoni M, Vittoria E, Volante M, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology. 2014;100(4):310–6.

    Article  PubMed  CAS  Google Scholar 

  67. Woischke C, Schaaf CW, Yang HM, et al. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol. 2017;30(1):95–103.

    Article  PubMed  CAS  Google Scholar 

  68. Takizawa N, Ohishi Y, Hirahashi M, et al. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol. 2015;46(12):1890–900.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Brent K. Larson

  2. The University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

    Deepti Dhall

Authors
  1. Brent K. Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepti Dhall
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, CA, USA

    Hanlin L. Wang

  2. Mayo Clinic, Rochester, MN, USA

    Zongming Eric Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Larson, B.K., Dhall, D. (2021). Neuroendocrine Neoplasms of the Gastrointestinal Tract. In: Wang, H.L., Chen, Z.E. (eds) Practical Gastrointestinal Pathology. Practical Anatomic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-51268-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-51268-2_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-51267-5

  • Online ISBN: 978-3-030-51268-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation